Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/e62925564ecb1ec6ce1d956cde68e06b/44759/2026-granddad-child-reading-landscape-scaled.jpg'); }

Changing the course of cancer treatmentWe explore the power of the immune system to improve long-term survival of cancer patients, while preserving health and quality of life.
About us
<picture><source type="image/webp" srcSet="/static/dfc6aebe4089363632614b776a8f8f08/d443a/Screenshot-2026-06-25-145340-e1782392692113.webp 178w,/static/dfc6aebe4089363632614b776a8f8f08/0819c/Screenshot-2026-06-25-145340-e1782392692113.webp 356w,/static/dfc6aebe4089363632614b776a8f8f08/b0b85/Screenshot-2026-06-25-145340-e1782392692113.webp 712w" sizes="(min-width: 712px) 712px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 712px) 712px, 100vw" decoding="async" loading="lazy" src="/static/dfc6aebe4089363632614b776a8f8f08/a28c8/Screenshot-2026-06-25-145340-e1782392692113.png" srcSet="/static/dfc6aebe4089363632614b776a8f8f08/8ffb0/Screenshot-2026-06-25-145340-e1782392692113.png 178w,/static/dfc6aebe4089363632614b776a8f8f08/b655a/Screenshot-2026-06-25-145340-e1782392692113.png 356w,/static/dfc6aebe4089363632614b776a8f8f08/a28c8/Screenshot-2026-06-25-145340-e1782392692113.png 712w" alt=""/></picture>
Mendus presents data on vididencel in high-risk ovarian cancerMore details
<picture><source type="image/webp" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/bde29/061008-Hans-COO.webp 227w,/static/4500665f26ce306f14cdb18f8de4615d/58906/061008-Hans-COO.webp 454w,/static/4500665f26ce306f14cdb18f8de4615d/b7017/061008-Hans-COO.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO.jpg" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/1c00b/061008-Hans-COO.jpg 227w,/static/4500665f26ce306f14cdb18f8de4615d/e7daf/061008-Hans-COO.jpg 454w,/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO.jpg 907w" alt=""/></picture>
Hans Preusting appointed COORead the press release
<picture><source type="image/webp" srcSet="/static/68f26fe34509e1e6556b7b770d71a6ed/bde29/260911-VITAL-CML-stage-1-WEBSITE.webp 227w,/static/68f26fe34509e1e6556b7b770d71a6ed/58906/260911-VITAL-CML-stage-1-WEBSITE.webp 454w,/static/68f26fe34509e1e6556b7b770d71a6ed/b7017/260911-VITAL-CML-stage-1-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/68f26fe34509e1e6556b7b770d71a6ed/b4646/260911-VITAL-CML-stage-1-WEBSITE.jpg" srcSet="/static/68f26fe34509e1e6556b7b770d71a6ed/1c00b/260911-VITAL-CML-stage-1-WEBSITE.jpg 227w,/static/68f26fe34509e1e6556b7b770d71a6ed/e7daf/260911-VITAL-CML-stage-1-WEBSITE.jpg 454w,/static/68f26fe34509e1e6556b7b770d71a6ed/b4646/260911-VITAL-CML-stage-1-WEBSITE.jpg 907w" alt=""/></picture>
Positive VITAL-CML read-out supports advancement of CML programRead more
<picture><source type="image/webp" srcSet="/static/ab091f0d621005acb04361459d7af797/bde29/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE.webp 227w,/static/ab091f0d621005acb04361459d7af797/58906/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE.webp 454w,/static/ab091f0d621005acb04361459d7af797/b7017/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/ab091f0d621005acb04361459d7af797/b4646/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE.jpg" srcSet="/static/ab091f0d621005acb04361459d7af797/1c00b/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE.jpg 227w,/static/ab091f0d621005acb04361459d7af797/e7daf/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE.jpg 454w,/static/ab091f0d621005acb04361459d7af797/b4646/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE.jpg 907w" alt=""/></picture>
Mendus publishes financial report for Q2 2026Read the press release here
<picture><source type="image/webp" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/bde29/260716-Mendus-SAHMRI-WEBSITE.webp 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/58906/260716-Mendus-SAHMRI-WEBSITE.webp 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b7017/260716-Mendus-SAHMRI-WEBSITE.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE.jpg" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/1c00b/260716-Mendus-SAHMRI-WEBSITE.jpg 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/e7daf/260716-Mendus-SAHMRI-WEBSITE.jpg 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE.jpg 907w" alt=""/></picture>
Mendus to collaborate with SAHMRI in preparation for VITAL-TFR2 trialLearn more here
<picture><source type="image/webp" srcSet="/static/dfc6aebe4089363632614b776a8f8f08/d443a/Screenshot-2026-06-25-145340-e1782392692113.webp 178w,/static/dfc6aebe4089363632614b776a8f8f08/0819c/Screenshot-2026-06-25-145340-e1782392692113.webp 356w,/static/dfc6aebe4089363632614b776a8f8f08/b0b85/Screenshot-2026-06-25-145340-e1782392692113.webp 712w" sizes="(min-width: 712px) 712px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 712px) 712px, 100vw" decoding="async" loading="lazy" src="/static/dfc6aebe4089363632614b776a8f8f08/a28c8/Screenshot-2026-06-25-145340-e1782392692113.png" srcSet="/static/dfc6aebe4089363632614b776a8f8f08/8ffb0/Screenshot-2026-06-25-145340-e1782392692113.png 178w,/static/dfc6aebe4089363632614b776a8f8f08/b655a/Screenshot-2026-06-25-145340-e1782392692113.png 356w,/static/dfc6aebe4089363632614b776a8f8f08/a28c8/Screenshot-2026-06-25-145340-e1782392692113.png 712w" alt=""/></picture>
Mendus presents data on vididencel in high-risk ovarian cancerMore details
<picture><source type="image/webp" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/bde29/061008-Hans-COO.webp 227w,/static/4500665f26ce306f14cdb18f8de4615d/58906/061008-Hans-COO.webp 454w,/static/4500665f26ce306f14cdb18f8de4615d/b7017/061008-Hans-COO.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO.jpg" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/1c00b/061008-Hans-COO.jpg 227w,/static/4500665f26ce306f14cdb18f8de4615d/e7daf/061008-Hans-COO.jpg 454w,/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO.jpg 907w" alt=""/></picture>
Hans Preusting appointed COORead the press release

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW-1.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW-1.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW-1.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW-1.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW-1.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW-1.jpg 960w" alt=""/></picture>
Gaining the 
upper handToday, tumor recurrence is the main cause of cancer-related deaths. We aim to reduce tumor recurrence by harnessing the immune system to act against residual cancer cells.
What we do

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors

Latest newsNews and Events
No articles found

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile-1.jpg'); }

What we do

Changing the course of cancer treatment

Mendus presents data on vididencel in high-risk ovarian cancer

Hans Preusting appointed COO

Positive VITAL-CML read-out supports advancement of CML program

Mendus publishes financial report for Q2 2026

Mendus to collaborate with SAHMRI in preparation for VITAL-TFR2 trial

Mendus presents data on vididencel in high-risk ovarian cancer

Hans Preusting appointed COO

Gaining the upper hand

Invest in future cancer care

Latest news

What we do

Gaining the
upper hand